Alyeska Investment Group
TPTX

Alyeska Investment Group’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Alyeska Investment Group’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-50,000
Closed -$3.23M – 627
2020
Q2 		$3.23M Buy
+50,000
New +$2.88M 0.05% 311
2020
Q1 		– Sell
-27,851
Closed -$1.74M – 513
2019
Q4 		$1.74M Sell
27,851
-147,786
-84% -$7.03M 0.02% 303
2019
Q3 		$6.6M Buy
175,637
+75,337
+75% +$3.28M 0.1% 196
2019
Q2 		$4.08M Buy
+100,300
New +$3.58M 0.05% 260

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Alyeska Investment Group's TPTX Position: Q3 2020 in Review

Alyeska Investment Group sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2020, closing a stake of 50,000 shares — an estimated $3.23M sold.

Alyeska Investment Group first reported a position in TPTX in Q2 2019 and held it in 4 quarters. The position peaked at $6.6M in Q3 2019. 166 funds tracked by Wall St. Rank hold TPTX as of Q3 2020.

  • Alyeska Investment Group reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Alyeska Investment Group sold 50,000 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $3.23M.
  • Alyeska Investment Group first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 4 quarters.
  • Alyeska Investment Group's Turning Point Therapeutics, Inc. Common Stock position peaked at $6.6M in Q3 2019.
  • 166 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Alyeska Investment Group's 13F filing for Q3 2020, filed 16 Nov 2020.